"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
- Patient Information:
Details with Side Effects
There is no known antidote for MESNEX.
In a clinical trial, 11 patients received intravenous MESNEX 10 mg/kg to 66 mg/kg per day for 3 to 5 days. Patients also received ifosfamide or cyclophosphamide. Adverse reactions included nausea, vomiting, diarrhea and fever. An increased rate of these adverse reactions has also been found in oxazaphosphorinetreated patients receiving ≥ 80 mg MESNEX per kg per day intravenously compared with patients receiving lower doses or hydration treatment only.
Last reviewed on RxList: 4/1/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Mesnex Information
Mesnex - User Reviews
Mesnex User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.